A practical reference on GLP-1 receptor agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-09 and is reviewed periodically as new material appears.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | 31 amino acids |
| Backbone modification | Aib at position 8 | Blocks DPP-4 cleavage |
| Fatty acid chain | C18 diacid | Supports albumin binding |
| Native half-life | 1 to 2 minutes | Endogenous GLP-1 |
| Analog half-life | Approximately one week | Extended by albumin binding |
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
== Side effects == Very common (incidence > 10%) adverse effects include constipation, dry mouth, and drowsiness at the beginning of treatment. Common (1% < incidence ≤ 10%) adverse effects include drowsiness during maintenance therapy, tremor, headache, dizziness, vertigo, and weakness. Uncommon (0.1% < incidence ≤ 1%) adverse effects include weight gain.
Nigel Farage announces that Reform UK would preclude anyone arriving into the UK by illegal means from claiming asylum, with plans to deport 600,000 people over five years. Farage says that in order to deport 600,000 asylum seekers, a government headed by his party would leave the European Convention on Human Rights (ECHR) which may require a renegotiation of the terms of the Good Friday Agreement which has the ECHR written into it. 27 August – Former British Prime Minister Tony Blair joins a White House meeting with US President Donald Trump to discuss post-war Gaza. Liberal Democrat leader Sir Ed Davey announces he will boycott the banquet for Donald Trump's state visit to the United Kingdom in order to "send a message" over the humanitarian crisis in Gaza. Scottish Conservative MSP Graham Simpson defects to Reform UK. Farage rules out deporting children as part of Reform's deportation policy. 28 August – Starmer is to replace his principal private secretary, Nin Pandit, after ten months in the role. She follows the departures of chief of staff, Sue Gray, in October 2024 and director of communications, Matthew Doyle, in March, as the third Starmer-appointed senior staff member to be let go by him in less than a year. The UK, France and Germany begin the process of restoring UN sanctions against Iran following tension over its nuclear programme. MSP Colin Smyth has his Holyrood pass deactivated following allegations he placed a camera in a Scottish Parliament toilet.
==== 1935–1949 ==== Teva Pharmaceutical Industries took its present form through the efforts of Günther Friedländer and his aunt Else Kober on May 1, 1935. The original registration was under the name Teva Middle East Pharmaceutical & Chemical Works Co. Ltd. in Jerusalem, then part of Mandatory Palestine. Friedländer was a German pharmacist, botanist and pharmacognosist, who immigrated to Mandatory Palestine in 1934. The company was built with an investment of £4,900, which came from the family's own capital and partly from loans from other German immigrants. Capital shortage led to the joining of the banker Alfred Feuchtwanger as a partner in Teva, who received 33% of the shares in return for his investment. Friedländer's business philosophy opined that the pharmaceutical industry has a reliable basis in difficult economic times, since "A Jewish mother will always buy medicine for her children". In the Second World War, the company provided medicine to the allied forces and in particular to the British army present in the Middle East. After the war, Sir Alan Gordon Cunningham, the last of the High Commissioners for Palestine and Transjordan, visited Teva on behalf of the Secretary of State for the Colonies. His visit promoted Teva's reputation in the pharmaceutical market and created a momentum for Teva's development. During Mandatory Palestine, Teva exported its medical products to Arab countries. In 1941, Friedländer presented Teva products in an exhibition held in Cairo, Egypt.
== Used carrier proteins == Keyhole limpet hemocyanin It is copper-containing respiratory protein, isolated from keyhole limpets (Megathura crenulata). Because of its evolutionary distance from mammals, high molecular weight and complex structure it is usually immunogenic in vertebrate animals. Concholepas concholepas hemocyanin (also blue carrier immunogenic orotein) It is alternative to KLH isolated from Concholepas concholepas. It has the similar immunogenic properties as KLH but better solubility and therefore better flexibility. Bovine serum albumin It is from the blood sera of cows and has similarly immunogenic properties as KLH or CCH. The cationized form of BSA (cBSA) is highly positively charged protein with significantly increased immunogenicity. This change possesses a greater number of possible conjugated antigens to the protein. Ovalbumin Also known as egg albumin, OVA is the main protein (60-75%) found in hen egg white. OVA is soluble in dimethyl sulfoxide (DMSO), which enables the conjugation of haptens that are not soluble in aqueous buffers. The immune response can be enhanced using an adjuvant injected together with the immunogen.
In 1997 General Charles Guthrie became Chief of the Defence Staff the head of the British armed forces. Lieutenant-General Cedric Delves was appointed commander of the Field Army and deputy commander in chief NATO Regional Headquarters Allied Forces North in 2002–2003.
Sources: en.wikipedia.org
== Further reading == Kielley WW, Bradley LB (1954). "Glutathione thiolesterase". J. Biol. Chem. 206 (1): 327–33. doi:10.1016/S0021-9258(18)71321-5. PMID 13130552. Murata, Kousaku; Sato, Nobuyuki; Rhee, Hae-ik; Watanabe, Kunihiko; Kimura, Akira (1987). "Purification and Characterization of Glutathione Thiol Esterase from Saccharomyces cerevisiae". Agricultural and Biological Chemistry. 51 (7): 1901–1907. doi:10.1080/00021369.1987.10868321. Uotila, Lasse (1979). "Glutathione thiol esterases of human red blood cells". Biochimica et Biophysica Acta (BBA) - Protein Structure. 580 (2): 277–288. doi:10.1016/0005-2795(79)90140-5. PMID 93000.
==== MeSH E05.300.530 – injections ==== MeSH E05.300.530.370 – injections, intra-arterial MeSH E05.300.530.380 – injections, intra-articular MeSH E05.300.530.430 – injections, intralesional MeSH E05.300.530.440 – injections, intralymphatic MeSH E05.300.530.460 – injections, intramuscular MeSH E05.300.530.490 – injections, intraperitoneal MeSH E05.300.530.540 – injections, intravenous MeSH E05.300.530.550 – injections, intraventricular MeSH E05.300.530.580 – injections, spinal MeSH E05.300.530.580.300 – injections, epidural MeSH E05.300.530.580.300.145 – blood patch, epidural MeSH E05.300.530.620 – injections, subcutaneous MeSH E05.300.530.620.410 – injections, intradermal MeSH E05.300.530.620.570 – injections, jet MeSH E05.300.530.620.570.100 – biolistics MeSH E05.300.530.690 – microinjections
=== Student Union Memorial Center === The Student Union Memorial Center, on the north side of the Mall east of Old Main, was completely reconstructed between 2000 and 2003. It replaced a 270,000-square-foot (25,000 m2) building that originally opened in 1951 and had been expanded during the 1960s and early 1970s. Designed to resemble the USS Arizona (BB-39), the building includes memorial features honoring members of the university community and others who served in the military. Memorial sculptures throughout the complex incorporate elements such as the sounds of chiming dog tags and refracted light. One of the center's best known features is the USS Arizona bell, which is housed in the building's clock tower. The 1,820-pound (826 kg) bell was one of two recovered from the battleship after the attack on Pearl Harbor and arrived on campus in July 1946. For decades, the bell was rung seven times on the third Wednesday of every month at 12:07 p.m., marking the time of the USS Arizona's sinking on December 7, 1941. The bell was also rung after Arizona Wildcats football home victories, except against other Arizona schools. In December 2020, the university ended the long-standing ringing tradition after the U.S. Navy, which still owns the bell, requested that the historic object be protected from further wear.
The unattended and remote nature of many data logger applications implies the need for some applications to operate from a DC power source, such as a battery. Solar power may be used to supplement these power sources. These constraints have generally led to ensuring that the devices they market are extremely power efficient relative to computers. In many cases, they are required to operate in harsh environmental conditions where computers will not function reliably. This unattended nature also dictates that data loggers must be extremely reliable. Since they may operate for long periods nonstop with little or no human supervision and may be installed in harsh or remote locations, it is imperative that so long as they have power, they will not fail to log data for any reason. Manufacturers go to great lengths to ensure that the devices can be depended on in these applications. As such data loggers are almost completely immune to the problems that might affect a general-purpose computer in the same application, such as program crashes and the instability of some operating systems.
Sources: en.wikipedia.org
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.
A fatty acid side chain attaches the peptide to serum albumin, which shields it from kidney filtration and protease activity. This interaction is the main reason its circulation time is extended.
No. The native hormone is GLP-1, and semaglutide is an engineered variant with three deliberate structural alterations. It does not appear in unmodified biological sources.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.